You are here

biotech

Biopharma’s top 5 IPOs of 2023 (so far)

Biopharma’s top 5 IPOs of 2023 (so far)

Pharma Voice

Apogee Therapeutics

Neumora Therapeutics

Mineralys Therapeutics

Flag link:

CEO Anne Wojcicki on turning 23andMe into a ‘full-fledged biotech’

CEO Anne Wojcicki on turning 23andMe into a ‘full-fledged biotech’

BioPharma Dive

Flag link:

Flagship expands into Asia-Pacific with new Singapore hub

Flagship expands into Asia-Pacific with new Singapore hub

BioPharma Dive

Flagship Pioneering

Flag link:

XBI biotech index rises, giving investors a shred of hope

XBI biotech index rises, giving investors a shred of hope

Stat

Flag link:

Why The Next Blockbuster Therapy May Come Out Of Singapore

Why The Next Blockbuster Therapy May Come Out Of Singapore

Forbes

Flag link:

The 2023 Biotech Graveyard

The 2023 Biotech Graveyard

Fierce Biotech

Rubius Therapeutics

Nabriva Therapeutics

Calithera Biosciences

Antios Therapeutics

Magenta Therapeutics

Coda Biotherapeutics

Aristea Therapeutics

Flag link:

Lessons from a biotech downturn: Funding challenges, an IPO dry spell and what to expect in 2024

Lessons from a biotech downturn: Funding challenges, an IPO dry spell and what to expect in 2024

BioPharma Dive

Flag link:

'By hook or by crook': BIO CEO urges biotechs to be flexible on funding to survive tough times

'By hook or by crook': BIO CEO urges biotechs to be flexible on funding to survive tough times

Fierce Biotech

Inflation Reduction Act

Flag link:

Biotech Accelerator Debuts in Houston

Biotech Accelerator Debuts in Houston

BioSpace

Rice University

Flag link:

A decade later, biotech’s CRISPR revolution is still going strong

A decade later, biotech’s CRISPR revolution is still going strong

BioPharma Dive

Flag link:

Massachusetts Biopharma Job Growth Surpasses that of Other States: Report

Massachusetts Biopharma Job Growth Surpasses that of Other States: Report

BioSpace

Flag link:

Biotech Bankruptcies Skyrocket

Biotech Bankruptcies Skyrocket

BioSpace

Avadel Specialty Pharmaceuticals

Sancilio Pharmaceuticals

Statera Biopharma

Flag link:

After pandemic sugar rush, a market 'hangover' opens biotech to funding approaches steeped in stigma

After pandemic sugar rush, a market 'hangover' opens biotech to funding approaches steeped in stigma

Fierce Biotech

venture capital

Flag link:

How biotech IPOs performed in the third quarter

How biotech IPOs performed in the third quarter

BioPharma Dive

Neumora Therapeutics

Mira Pharmaceuticals

Turnstone Biologics

Apogee Therapeutics

Sagimet Biosciences

60 Degrees Pharma

Flag link:

Biotech Financing, IPO Tide May Be Turning – Signs of a Potential Recovery?

Biotech Financing, IPO Tide May Be Turning – Signs of a Potential Recovery?

BioSpace

Neumora Therapeutics

Rome Therapeutics

Generate Biomedicines

Flag link:

‘It’s Like Ross Was Planning This Project.’ Perot Sr.’s HQ Finds New Life as Biotech Development

‘It’s Like Ross Was Planning This Project.’ Perot Sr.’s HQ Finds New Life as Biotech Development

D Magazine

Flag link:

Vivek Ramaswamy’s brashness made waves in the Republican debate. He did the same in biotech

Vivek Ramaswamy’s brashness made waves in the Republican debate. He did the same in biotech

Stat

Vivek Ramaswamy

2024 Presidential election

Flag link:

Mass Layoffs Continue Across The Biotech Sector. What Does This Mean For Pharma’s Future?

Mass Layoffs Continue Across The Biotech Sector. What Does This Mean For Pharma’s Future?

Forbes

Flag link:

Are biotech VCs headed for better times? In one firm’s success, lessons for turning crisis into profit

Are biotech VCs headed for better times? In one firm’s success, lessons for turning crisis into profit

Stat

venture capital

The Column Group

Flag link:

Pages